Trial Profile
Phase II Trial of Pembrolizumab in Combination With Doxorubicin in Advanced, Recurrent or Metastatic Endometrial Cancer (TOPIC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Doxorubicin (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Clear cell sarcoma; Endometrial cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms TOPIC
- 04 Oct 2021 Status changed from active, no longer recruiting to completed.
- 21 Sep 2021 Primary endpoint has been met. (PFS rate at 6 months according to RECIST 1.1 criteria), as per Results presented at the 46th European Society for Medical Oncology Congress
- 21 Sep 2021 Results presented at the 46th European Society for Medical Oncology Congress